Platelet glycoprotein IIb/IIIa receptor blockers: An appropriate-use model for expediting care in acute coronary syndromes

American Heart Journal

Volumn 139, Issue 2 II, 2000, Pages

  Kereiakes, D J ^a   McDonald, M ^a   Broderick, T ^a   Roth, E M ^a   Whang, D D ^a   Martin, L H ^a   Howard, W L ^a   Schneider, J ^a   Shimshak, T ^a   Abbottsmith, C W ^a  

^a The Carl & Edyth Lindner Center for Research & Education   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABCIXIMAB; FIBRINOGEN RECEPTOR ANTAGONIST; SELECTIN;

ADULT; ANGIOGRAPHY; CONFERENCE PAPER; CORONARY STENT; FEMALE; HEART MUSCLE ISCHEMIA; HUMAN; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; Q WAVE; REVASCULARIZATION; ST SEGMENT; THROMBOCYTE ACTIVATION; THROMBOCYTE FUNCTION; TREATMENT OUTCOME; UNSTABLE ANGINA PECTORIS;

EID: 0033983731     PISSN: 00028703     EISSN: None     Source Type: Journal    
DOI: 10.1067/mhj.2000.103741     Document Type: Conference Paper

References (51)

1. Lu Y, Theroux P, Xiao Z, Ghitescu M. Increased expression of GP IIb/IIIa platelet membrane receptor in acute ischemic syndromes [abstract]. Circulation 1996;94:(suppl I):I-515.
2. Pizulli L, Yang A, Martin JF, Luderitz B. Changes in platelet size and count in unstable angina compared to stable angina or non-cardiac chest pain. Eur Heart J 1998;19:80-4.
3. Ault KA, Cannon CP, Mitchell J, et al. Platelet activation in patients after an acute coronary syndrome: results from the TIMI-12 trial. J Am Coll Cardiol 1999;33:634-9.
4. Myler RK, Shaw RE, Stertzer SH, Bashour TT, Ryan C, Hecht HS. Unstable angina and coronary angioplasty. Circulation 1990;82(suppl II):88-95.
5. Hartzler GO, Rutherford BD, McConahay DR, Johnson WL, Giorgi LV. "High risk" percutaneous transluminal coronary angioplasty. Am J Cardiol 1988;61:33G-37G.
6. Adele C, Vaitkus PT, Wells SW, Zehnacker JB. Cost advantages of an ad hoc angioplasty strategy. J Am Coll Cardiol 1998; 31:321-5.
7. Singh M, Holmes DR, Garratt KN, Bell MR, Berger PB, Rihal CS, et al. Stents versus conventional PTCA in unstable angina [abstract]. J Am Cardiol 1998;33:29A.
8. Angioi M, Danchin N, Gangloff C, et al. Ticlopidine-aspirin as antithrombotic regimen for intracoronary stenting for unstable angina: is there a need for further antiplatelet therapy [abstract]? J Am Coll Cardiol 1998;31:100A.
9. Kastrati A, Neumann FJ, Schomig A. Operator volume and outcome of patients undergoing coronary stent placement. J Am Coll Cardiol 1998;32:970-6.
10. Lincoff AM, Califf RM, Anderson K, Weisman HF, Topol EJ, for the EPIC Investigators. Striking clinical benefit with platelet GP IIb/IIIa inhibition by c7E3 among patients with unstable angina: outcome in the EPIC trial. [abstract]. Circulation 1994;90 suppl I:I-21.
11. The EPILOG Investigators. Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization. N Engl J Med 1997;336:1689-96.
12. Lincoff AM, Califf RM, Anderson KM, et al for the EPIC Investigators. Evidence for prevention of death and myocardial infarction with platelet membrane glycoprotein IIb/IIIa receptor blockade by abciximab (7E3 Fab) among patients with unstable angina undergoing percutaneous coronary revascularization. J Am Coll Cardiol 1997;30:149-56.
13. Topol EJ, Ferguson JJ, Weisman HF, et al for the EPIC investigator group. Long-term protection from myocardial ischemic events in a randomized trial of β integrin 3 blockade with percutaneous coronary intervention. JAMA 1997;278:479-84.
14. The IMPACT-II Investigators. Randomized placebo-controlled trial of effect of eptifibatide on complications of percutaneous coronary intervention: IMPACT-II. Lancet 1997;349:1422-8.
15. The RESTORE Investigators. Effect of platelet glycoprotein IIb/IIIa blockade with tirofiban on adverse cardiac events in patients with unstable angina or acute myocardial infarction undergoing coronary angioplasty. Circulation 1997;96:1445-53.
16. EPIC investigators. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. N Engl J Med 1994;330:956-61.
17. CAPTURE investigators. Randomized placebo-controlled trial of abciximab before and during coronary intervention in refractory unstable angina: the CAPTURE Study. Lancet 1997;349:1429-35.
18. EPISTENT investigators. Randomized placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein IIb/IIIa blockade. Lancet 1998;352:87-92.
19. Brener SJ, Barr LA, Burchenal J, Kath S, George BS, Jones AA, et al. A randomized, placebo-controlled trial of abciximab with primary angioplasty for acute MI: the RAPPORT trial [abstract]. Circulation 1997; 96(suppl I):I-473.
20. Kereiakes DJ, Lincoff AM, Tcheng J, Topol EJ. GP IIb/IIIa blockage during coronary intervention for unstable angina: longer is not better. [abstract]. Am J Cardiol 1998;82 suppl:95S.
21. Mascelli M, Lance ET, Damaraju L, Wagner CL, Weisman HF, Jordan RE. Pharmacodynamic profile of short-term abciximab treatment demonstrates prolonged platelet inhibition with gradual recovery from GP IIb/IIIa receptor blockade. Circulation 1998;97: 1680-8.
22. 3 integrin receptors: a potential mechanism for the prevention of restenosis [abstract]. J Am Coll Cardiol 1997;29:A243.
23. Reverter JC, Beguin S, Kessels H, Kuman R, Hemker HC, Coller BS. Inhibition of platelet-mediated, tissue factor-induced thrombin generation by the mouse/human chimeric 7E3 Fab treatment of an acute thrombosis and "clinical restenosis." J Clin Invest 1996; 98:863-74.
24. Marijianowski MM, Nakada MT, Sundell BI, Kelly AB, Jordan RE, Jakubowski JA, et al. Abciximab reduces vascular lesion formation in non-human primates[abstract]. J Am Coll Cardiol 1999;33:69A.
25. 3 receptor blockade reduces restenosis following balloon angioplasty in the atherosclerotic rabbit [abstract]. J Am Coll Cardiol 1999;33:31A.
26. Shappell SB, Toman C, Anderson DC, Taylor AA, Entman ML, Smith CW. Mac-1 (CD11b/CD18) mediates adherence-dependent hydrogen peroxide production by human and canine neutrophils. J Immunol 1990;144:2702-11.
27. Simon DI, XU H, Ortlepp S, Rogers C, Rao NK. 7E3 monoclonal antibody directed against the platelet glycoprotein IIb/IIIa crossreacts with the leukocyte integrin Mac-1 and blocks adhesion to fibrinogen and ICAM-1. Thromb Vasc Biol 1997;17:528-35.
28. Mickelson JK, Ali MN, Kleiman NS, Lakkis NM, Chow TW, Hughes BJ, et al. Chimeric 7E3 Fab (ReoPro) decreases detectable CDIIb on neutrophils from patients undergoing coronary angioplasty. J Am Coll Cardiol 1999;33:97-106.
29. Farb A, Sangiorgi G, Carter AJ, Walley VM, Edwards WD, Schwartz RS, et al. Pathology of acute and chronic coronary stenting in humans. Circulation 1999;99:44-52.
30. Kereiakes DJ, McDonald M, Broderick T, Roth EM, Whang DD, Martin LH, et al. Abciximab provides cost efficient, safely expedited care for unstable angina [abstract]. Eur Heart J 1999;20:1542.
31. Kereiakes DJ. Preferential benefit of platelet glycoprotein IIb/IIIa receptor blockade: specific considerations by device and disease state. Am J Cardiol 1998;81:49E-54E.
32. Yusuf S, Flather M, Pogue J, Hunt D, Varigos J, Piegas L, et al for the Organization to Assess Strategies for Ischemic Syndromes (OASIS) registry investigators. Variations between countries in invasive cardiac procedures and outcomes in patients with suspected unstable angina or myocardial infarction without initial ST elevation. Lancet 1998;352:507-14.
33. Lundstrom RJ, Colby CJ, Jindeel A, Hay RL. Abciximab in unstable coronary syndromes: benefits and costs in a group model non-profit health maintenance organization [abstract]. J Am Coll Cardiol 1999;33:41A.
34. The PURSUIT investigators. Inhibition of platelet glycoprotein IIb/IIIa with eptifibatide in patients with acute coronary syndromes. N Engl J Med 1998;339:436-43.
35. Braunwald E, Mark DB, Jones RH, et al. Unstable angina: diagnosis and management. Agency for Health Care Policy and Research and the National Heart, Lung, and Blood Institute, Public Health Service. Rockville (MD): US Department of Health and Human Services; 1994. AHCPR Publication No. 94-0602.
36. van Domburg RT, Miltenburg-vanZijl AJ, Veerhoek RJ, Simoons ML. Unstable angina: good long-term outcome after a complicated early course. J Am Coll Cardiol 1998;31:1534-9.
37. Anderson HV, Cannon CP, Stone PH, Williams DO, McCabe CH, Knatterud EL, et al for the TIMI-IIIb investigators. One year results of the Thrombolysis in Myocardial Infarction (TIMI) IIIb clinical trial: a randomized comparison of tissue-type plasminogen activator versus placebo and early invasive versus early conservative strategies in unstable angina and non-Q wave myocardial infarction. J Am Coll Cardiol 1995;26:1643-50.
38. Bazzino O, Diaz R, Tajer C, et al for the ECLA collaborative group. Clinical predictors of in-hospital prognosis in unstable angina: ECLA 3. Am Heart J 1999;137:322-31.
39. Owa M, Origasa H, Saito M. Predictive validity of the Braunwald classification of unstable angina for angiographic findings, short-term prognoses, and treatment selection. Angiology 1997;48:663-71.
40. Dangas G, Mehran R, Wallenstein S, Courcoutsakis NA, Kakarala V, Hollywood J, et al. Correlation of angiographic morphology and clinical presentation in unstable angina. J Am Coll Cardiol 1997;29:519-25.
41. Viecili PRN, Leite PF, Pamplona D, Moretti MA, Park M, Borba F, et al. Prognostic value of admission electrocardiogram of 1072 patients with unstable angina and non-Q wave myocardial infarction [abstract]. J Am Coll Cardiol 1999;33:359A.
42. Ohman EM, Armstrong PW, Christenson RH, Grangert CB, Katus HA, Hamm CW, et al for the GUSTO IIa investigators. Cardiac troponin T levels for risk stratification in acute myocardial ischemia. GUSTO IIA investigators. N Engl J Med 1996; 335:1333-41.
43. Antman EM, Tanasijevic MJ, Thompson B, Schacyman M, McCabe CH, Cannon CP, et al. Cardiac-specific troponin I levels to predict the risk of mortality in patients with acute coronary syndromes. N Engl J Med 1996;335:1342-9.
44. Newby LK, Gibler WB, Christenson RH, Ohman EM. Serum markers for diagnosis and risk stratification in acute coronary syndromes. In: Cannon CP, editor. Management of acute coronary syndromes. Totowa (NJ): Humana Press; 1999. 147-71.
45. Roberts R, Fromm RE. Management of acute coronary syndromes based on risk stratification by biochemical markers: an idea whose time has come. Circulation 1998;98:1831-3.
46. Hamm CW, Goldmann BU, Heeschen C, Kreymann G, Berger J, Meinhertz T. Emergency room triage of patients with acute chest pain by means of rapid testing for cardiac troponin T or troponin I. N Engl J Med 1997;337:1648-53.
47. Lindahl B, Venge P, Wallentin L. Relation between troponin T and the risk of subsequent caridac events in unstable coronary artery disease. The FRISC study group. Circulation 1996;93:1651-7.
48. Lindahl B, Venge P, Wallentin L. Troponin T identifies patients with unstable coronary artery diesase who benefit from long-term antithrombotic protection. Fragmin in Unstable Coronary Artery Disease (FRISC) study group. J Am Coll Cardiol 1997;29:43-8.
49. Meinertz T, Hamm CW. Rapid testing for cardiac tropinins in patients with acute chest pain in the emergency room. Euro Heart J 1998;19:973-4.
50. Hamm CW, Heeschen C, Goldmann B, Vahanian A, Adgey J, Miguel CM, Rutsch W, et al for the C7E3 Fab Antiplatelet Therapy in Unstable Refractory Angina (CAPTURE) study investigators. Benefit of abciximab in patients with refractory unstable angina in relation to serum troponin T levels. New Engl J Med 1999;340: 1623-9.
51. Norgaard BL, Andersen K, Dellborg M, Abrahamsson P, Ravkilde J, Thygesen K, for the TRIM study group. Admission risk assessment by cardiac troponin T in unstable coronary artery disease: additional prognostic information from continuous ST segment monotroing. J Am Coll Cardiol 1999;33:1519-27.